Prophylaxis News and Research

RSS

Implementation of quality improvement intervention reduces medication use in premature babies: Study

A new study by Pediatrix Medical Group researchers has found that the implementation of a quality improvement intervention significantly reduces the use of a large number of medications in premature babies across a broad neonatal intensive care network.

3 May 2010

FDA issues complete response letter for Bristol-Myers Squibb's belatacept

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has issued a complete response letter regarding the Biologics License Application for belatacept in kidney transplantation.

3 May 2010

$EnzymeRx reports positive results from first clinical trial of pegsitacase for refractory gout$

EnzymeRx reports positive results from first clinical trial of pegsitacase for refractory gout

EnzymeRx, LLC, a clinical-stage biotechnology company, announced top line results from its first clinical trial of pegsitacase (formerly called Uricase‑PEG 20). Pegsitacase is a pegylated uricase being developed by EnzymeRx for the treatment of refractory gout and for the management of hyperuricemia associated with tumor lysis syndrome.

30 Apr 2010

Bristol-Myers Squibb reports 11% increase in first-quarter 2010 revenue

Bristol-Myers Squibb Company today reported strong sales and earnings growth for the first quarter of 2010.

30 Apr 2010

DENTSPLY International reports 7.7% increase in first-quarter 2010 net sales

DENTSPLY International Inc. today announced sales and earnings for the three months ended March 31, 2010. Net sales in the first quarter of 2010 increased 7.7% to $545.9 million compared to $506.9 million reported for the first quarter of 2009.

29 Apr 2010

Bristol-Myers Squibb to present on belatacept at American Transplant Congress

Bristol-Myers Squibb Company announced today that belatacept, an investigational selective T cell co-stimulation blocker being studied for use in solid organ transplantation, will be the subject of eight clinical presentations related to kidney transplantation at the American Transplant Congress, being held May 1 - 5 in San Diego.

29 Apr 2010

Watson Laboratories sued in connection with filing of ANDA for generic version of Rapamune tablets

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc. - Florida, has been sued by Pfizer Inc. and Wyeth Pharmaceuticals Inc. in connection with the filing of Watson's Abbreviated New Drug Application for sirolimus tablets in the 1 mg and 2 mg strengths.

29 Apr 2010

ViroPharma initiates multi-dose Phase 2 study of Cinryze in patients with HAE

ViroPharma Incorporated today announced that it has initiated an open-label, multi-dose Phase 2 study to evaluate the safety, and pharmacokinetics and pharmacodynamics of subcutaneous versus intravenous administration of Cinryze (C1 esterase inhibitor [human)] in 24 adolescents and adult subjects with hereditary angioedema.

27 Apr 2010

FDA approves Novartis Pharmaceuticals' Zortress for preventing rejection of kidney transplants

The US Food and Drug Administration (FDA) has approved Zortress® (everolimus) oral tablets for the prevention of rejection of kidney transplants in adult patients at low-to-moderate immunologic risk. Zortress is to be given in combination with reduced doses of the calcineurin inhibitor (CNI) cyclosporine, as well as basiliximab and corticosteroids.

22 Apr 2010

Merck to market and distribute MBL's Td vaccine in the U.S.

MassBiologics of the University of Massachusetts Medical School and Merck & Co., Inc. announced today that they have entered into an agreement that provides Merck with exclusive rights to market and distribute MBL's tetanus and diphtheria toxoids adsorbed (Td) vaccine in the United States, with the exception of Massachusetts, where MBL will continue distributing the vaccine.

21 Apr 2010

European patent for XenoPort's investigational compound is valid

XenoPort, Inc. announced today that the European Patent Office (EPO) Opposition Division ruled that the European patent for the composition of matter of XP13512 (European Patent No. 1 404 324) is valid.

16 Apr 2010

M2010 to encompass broader spectrum of HIV prevention research

HIV prevention researchers, policy makers and community advocates from more than 35 countries will be in Pittsburgh, May 22-25 to attend the 2010 International Microbicides Conference.

15 Apr 2010

Cempra to make poster presentations on CEM-101 and CEM-102 at ECCMID 2010

Cempra Pharmaceuticals today announced poster presentations on its novel antibiotic CEM-101, a next-generation macrolide, and CEM-102, the company's proprietary front-loading oral dosing regimen of sodium fusidate, at the 20th European Congress of Clinical Microbiology and Infectious Disease, April 10 to 13, 2010, in Vienna Austria.

12 Apr 2010

PESA CNIC-Santander trial initiative to increase knowledge about cardiovascular diseases

Felipe P-triz, Secretary of State for Research and Emilio Bot-n, President of the Grupo Santander, signed today a milestone agreement giving birth to the PESA (Progression of Early Subclinical Atherosclerosis) CNIC-Santander trial. The project's main goal is to increase the knowledge about cardiovascular diseases.

9 Apr 2010

Mobile compression device effective in preventing blood clots after hip replacement surgery

A mobile compression device is as effective as medication at preventing the formation of blood clots after hip replacement surgery but provides greater patient safety, according to a study in the March issue of the Journal of Bone & Joint Surgery.

7 Apr 2010

Bloomberg examines potential benefits, drawbacks to PrEP

"Gilead Sciences Inc. may learn this year whether its drugs for treating HIV can also stop people from catching the virus in the first place," Bloomberg writes in a piece that examines the potential benefits and drawbacks to using low-doses of HIV/AIDS medications to reduce a person's risk of becoming infected with HIV. According to the news service, the initial results of 10 trials including more than 20,000 people could be available as early as July.

2 Apr 2010

Positive results from Ardea Biosciences' Phase 2b study of RDEA594 for hyperuricemia and gout

Ardea Biosciences, Inc. announced positive, preliminary, top-line results from its Phase 2b monotherapy study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout. In this 28-day, randomized, double-blind, placebo-controlled, dose-escalation study, 123 gout patients with hyperuricemia (serum urate levels greater than or equal to 8 mg/dL) received 200 mg once-daily (qd) RDEA594, 400 mg qd RDEA594, 600 mg qd RDEA594 or matching placebo.

1 Apr 2010

ViroPharma initiates Phase 2 clinical study to evaluate Cinryze

ViroPharma Incorporated today announced that it has initiated an open-label, single-dose Phase 2 study to evaluate doses of Cinryze™ (C1 esterase inhibitor [human)] for treatment of acute angioedema attacks in children less than 12 years of age with hereditary angioedema.

31 Mar 2010

SCYNEXIS presents overview of novel cyclophilin inhibitor at Hepatitis C Conference

Drug discovery company, SCYNEXIS, Inc. announced today that management will present an overview on the Company's lead anti-hepatitis C virus (HCV) candidate, SCY-635, at the upcoming Canaccord Adams' Hepatitis C Conference on Thursday, April 1, 2010 at 11:15 am ET at the Peninsula Hotel in New York City.

31 Mar 2010

Preclinical study of DAS181 for treatment and prevention of ILI published

NexBio, Inc. announced today the publication in the Journal of Infectious Diseases of a preclinical study suggesting that treatment with DAS181 (Fludase®) may reduce the risk of secondary bacterial pneumonia following influenza virus infection.

30 Mar 2010

Prophylaxis News and Research

Implementation of quality improvement intervention reduces medication use in premature babies: Study

FDA issues complete response letter for Bristol-Myers Squibb's belatacept

EnzymeRx reports positive results from first clinical trial of pegsitacase for refractory gout

Bristol-Myers Squibb reports 11% increase in first-quarter 2010 revenue

DENTSPLY International reports 7.7% increase in first-quarter 2010 net sales

Bristol-Myers Squibb to present on belatacept at American Transplant Congress

Watson Laboratories sued in connection with filing of ANDA for generic version of Rapamune tablets

ViroPharma initiates multi-dose Phase 2 study of Cinryze in patients with HAE

FDA approves Novartis Pharmaceuticals' Zortress for preventing rejection of kidney transplants

Merck to market and distribute MBL's Td vaccine in the U.S.

European patent for XenoPort's investigational compound is valid

M2010 to encompass broader spectrum of HIV prevention research

Cempra to make poster presentations on CEM-101 and CEM-102 at ECCMID 2010

PESA CNIC-Santander trial initiative to increase knowledge about cardiovascular diseases

Mobile compression device effective in preventing blood clots after hip replacement surgery

Bloomberg examines potential benefits, drawbacks to PrEP

Positive results from Ardea Biosciences' Phase 2b study of RDEA594 for hyperuricemia and gout

ViroPharma initiates Phase 2 clinical study to evaluate Cinryze

SCYNEXIS presents overview of novel cyclophilin inhibitor at Hepatitis C Conference

Preclinical study of DAS181 for treatment and prevention of ILI published

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News